TECHNOLOGY

Technology


Technology Snapshot

GlycoConnect™

HydraSpace™

toxSYN™ Payloads

Metal-Free Click


toxSYN™ ADC Payload Platform

The toxSYN™ platform comprises ADC payloads that span multiple modes of action and where the majority are clinically validated.  Together with the company’s other ADC enabling technologies, these offer a consolidated licensing solution for translating any antibody into a highly competitive, proprietary ADC product. 

Each toxSYN™ linker-payload is functionalized to allow facile conjugation using the company’s GlycoConnect™ technology. Furthermore, these may include linkers that are of non-cleavable or cleavable nature (i.e. designed for intracellular/lysosomal release of the active catabolite).

Mode-of-Action toxSYN™
Linker-Payload
Payload
(Active Catabolite)
Topoisomerase inhibition SYNtecan™ P undisclosed
camptothecin
SYN-38™ SN-38
DNA damaging SYN-PNU™ PNU-159,682
SYNeamicin D™ P calicheamicin γ1I
SYNeamicin G™ P calicheamicin γ1I
Microtubule inhibition SYNstatin E™ MMAE
SYNstatin F™ MMAF
SYNtansine™ maytansinoid *

*N-6-aminohexanoyl-maytansine (Ahx-maytansine)
P Patent protection filed by Synaffix, beyond the claims of GlycoConnect™ and HydraSpace™

synaffix-core-graphic-payload-dar2

synaffix-core-graphic-payload-dar4

synaffix-core-graphic-payload-dar2-2

PLEASE NOTE: these illustrations represent an artist’s rendition